« Return to News | CROs/Service Providers

Covance's Q1 Profit Drops, Cuts 2009 Forecast

Thursday, April 30, 2009 07:10 AM

Covance's first quarter profit fell 18%, and the company reduced its 2009 profit guidance. In after hours trading, Covance's shares fell 8.2% to $37.

The contract research organization (CRO) recorded first quarter net income of $40.3 million, or 63 cents a share, down from $49.1 million, or 76 cents a share, a year ago.

Covance cut its 2009 profit guidance to $2.50 to $2.70 per share from $3.00 to $3.20 per share.

First quarter net revenue was up 7% to $468.4 million, but early stage revenue, where Covance is traditionally strong, slipped 5% to $192.5 million.

Joe Herring, Chairman and CEO, Covance, stated, "First quarter results were impacted by reduced market demand in Early Development, resulting in year-on-year and sequential declines in revenue and profitability, offset by record results in Late-Stage Development. Our forecast for Early Development results is to be sequentially flat in the second quarter, followed by sequential growth in the third and fourth quarters. In Late-Stage Development, increased demand led to accelerated revenue growth of 18.2% in the quarter (25% excluding the impact of foreign exchange) and exceptional operating margins of 22.6%."

The company's backlog at March 31 grew 54.4% year-over-year to $4.42 billion compared with $2.86 billion at March 31, 2008 and $4.33 billion at year-end.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.